دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Public Health Law after Covid-19
Michelle M. Mello, J.D., Ph.D., and Wendy E. Parmet, J.D.
doi : 10.1056/NEJMp2112193
N Engl J Med 2021; 385:1153-1155
Revitalizing the U.S. Primary Care Infrastructure
Kevin Grumbach, M.D., Thomas Bodenheimer, M.D., M.P.H., Deborah Cohen, Ph.D., Robert L. Phillips, M.D., M.S.P.H., Kurt C. Stange, M.D., Ph.D., and John M. Westfall, M.D., M.P.H.
doi : 10.1056/NEJMp2109700
N Engl J Med 2021; 385:1156-1158
Mask Wars
David S. Jones, M.D., Ph.D., and Scott H. Podolsky, M.D.
doi : 10.1056/NEJMp2112052
N Engl J Med 2021; 385:1159-1161
Evidence of Artemisinin-Resistant Malaria in Africa
Betty Balikagala, M.D., Ph.D., Naoyuki Fukuda, M.D., D.T.M.H., Ph.D., Mie Ikeda, Ph.D., Osbert T. Katuro, B.Sc., Shin-Ichiro Tachibana, Ph.D., Masato Yamauchi, M.P.H., Ph.D., Walter Opio, M.D., Sakurako Emoto, M.D., Denis A. Anywar, M.Sc., Eisaku Kimura, M.D., Ph.D., Nirianne M.Q. Palacpac, Ph.D., Emmanuel I. Odongo-Aginya, Ph.D., Martin Ogwang, M.D., M.M.E.D., Toshihiro Horii, Ph.D., and Toshihiro Mita, M.D., Ph.D.
doi : 10.1056/NEJMoa2101746
N Engl J Med 2021; 385:1163-1171
In the six Southeast Asian countries that make up the Greater Mekong Subregion, Plasmodium falciparum has developed resistance to derivatives of artemisinin, the main component of first-line treatments for malaria. Clinical resistance to artemisinin monotherapy in other global regions, including Africa, would be problematic.
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Paul T. Heath, F.R.C.P.C.H., Eva P. Galiza, M.B., B.S., David N. Baxter, M.D., Ph.D., Marta Boffito, M.D., Ph.D., Duncan Browne, M.D., Fiona Burns, Ph.D., David R. Chadwick, Ph.D., Rebecca Clark, M.B., Ch.B., Catherine Cosgrove, Ph.D., James Galloway, Ph.D., Anna L. Goodman, D.Phil., Amardeep Heer, M.B., Ch.B., Andrew Higham, Ph.D., Shalini Iyengar, M.B., B.S., Arham Jamal, M.B., B.Ch., Christopher Jeanes, M.B., B.S., Philip A. Kalra, M.D., Christina Kyriakidou, M.D., Daniel F. McAuley, M.D., Agnieszka Meyrick, M.D., Angela M. Minassian, D.Phil., Jane Minton, Ph.D., Patrick Moore, B.M., B.Sc., Imrozia Munsoor, M.B., B.S., Helen Nicholls, M.B., B.Ch., Orod Osanlou, M.B., Ch.B., Jonathan Packham, D.M., Carol H. Pretswell, M.B., Ch.B., Alberto San Francisco Ramos, L.M.S., Dinesh Saralaya, M.D., Ray P. Sheridan, M.B., Ch.B., Richard Smith, Ph.D., Roy L. Soiza, M.B., Ch.B., Pauline A. Swift, Ph.D., Emma C. Thomson, Ph.D., Jeremy Turner, D.Phil., Marianne E. Viljoen, M.B., Ch.B., Gary Albert, M.S., Iksung Cho, M.S., Filip Dubovsky, M.D., Greg Glenn, M.D., Joy Rivers, Ph.D., Andreana Robertson, M.S., Kathy Smith, M.D., and Seth Toback, M.D. for the 2019nCoV-302 Study Group*
doi : 10.1056/NEJMoa2107659
N Engl J Med 2021; 385:1172-1183
Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvant, showed that the vaccine was safe and associated with a robust immune response in healthy adult participants. Additional data were needed regarding the efficacy, immunogenicity, and safety of this vaccine in a larger population.
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
Meagan P. O’Brien, M.D., Eduardo Forleo-Neto, M.D., Bret J. Musser, Ph.D., Flonza Isa, M.D., Kuo-Chen Chan, Ph.D., Neena Sarkar, Ph.D., Katharine J. Bar, M.D., Ruanne V. Barnabas, M.D., Dan H. Barouch, M.D., Ph.D., Myron S. Cohen, M.D., Christopher B. Hurt, M.D., Dale R. Burwen, M.D., M.P.H., Mary A. Marovich, M.D., Peijie Hou, Ph.D., Ingeborg Heirman, Ph.D., John D. Davis, Ph.D., Kenneth C. Turner, Ph.D., Divya Ramesh, Ph.D., Adnan Mahmood, M.D., Andrea T. Hooper, Ph.D., Jennifer D. Hamilton, Ph.D., Yunji Kim, Pharm.D., Lisa A. Purcell, Ph.D., Alina Baum, Ph.D., Christos A. Kyratsous, Ph.D., James Krainson, M.D., Richard Perez-Perez, M.D., Rizwana Mohseni, D.O., Bari Kowal, M.S., A. Thomas DiCioccio, Ph.D., Neil Stahl, Ph.D., Leah Lipsich, Ph.D., Ned Braunstein, M.D., Gary Herman, M.D., George D. Yancopoulos, M.D., Ph.D., and David M. Weinreich, M.D. for the Covid-19 Phase 3 Prevention Trial Team*
doi : 10.1056/NEJMoa2109682
N Engl J Med 2021; 385:1184-1195
REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of hospitalization or death among high-risk persons with coronavirus disease 2019 (Covid-19). Whether subcutaneous REGEN-COV prevents severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and subsequent Covid-19 in persons at high risk for infection because of household exposure to a person with SARS-CoV-2 infection is unknown.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan, M.D., Ph.D., Jessica C. Hassel, M.D., Piotr Rutkowski, M.D., Ph.D., Jean-Francois Baurain, M.D., Ph.D., Marcus O. Butler, M.D., Max Schlaak, M.D., Ryan J. Sullivan, M.D., Sebastian Ochsenreither, M.D., Reinhard Dummer, M.D., John M. Kirkwood, M.D., Anthony M. Joshua, M.D., Ph.D., Joseph J. Sacco, M.D., Ph.D., Alexander N. Shoushtari, M.D., Marlana Orloff, M.D., Josep M. Piulats, M.D., Ph.D., Mohammed Milhem, M.D., April K.S. Salama, M.D., Brendan Curti, M.D., Lev Demidov, M.D., Lauris Gastaud, M.D., Cornelia Mauch, M.D., Ph.D., Melinda Yushak, M.D., M.P.H., Richard D. Carvajal, M.D., Omid Hamid, M.D., Shaad E. Abdullah, M.D., Chris Holland, M.S., Howard Goodall, M.D., and Sophie Piperno-Neumann, M.D. for the IMCgp100-202 Investigators*
doi : 10.1056/NEJMoa2103485
N Engl J Med 2021; 385:1196-1206
Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment are lacking. Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100–positive cells.
Perspectives on the Treatment of Malignant Pleural Mesothelioma
Sam M. Janes, M.D., Ph.D., Doraid Alrifai, M.D., Ph.D., and Dean A. Fennell, M.D., Ph.D.
doi : 10.1056/NEJMra1912719
N Engl J Med 2021; 385:1207-1218
Symblepharon in Linear IgA Bullous Dermatosis
Jonathan C. Tsui, M.D., and Spencer Onishi, D.O.
doi : 10.1056/NEJMicm2101873
N Engl J Med 2021; 385:1219
Ocular Thelaziasis
Zijing Huang, M.D., and Weiqi Chen, M.D.
doi : 10.1056/NEJMicm2032962
N Engl J Med 2021; 385:e39
Case 29-2021: A 12-Month-Old Boy with Fever and Developmental Regression
Madeleine I. Matthiesen, M.D., Randheer Shailam, M.D., and Holly Rothermel, M.D.
doi : 10.1056/NEJMcpc2107346
N Engl J Med 2021; 385:1220-1229
Emergence of Artemisinin-Resistant Plasmodium falciparum in East Africa
Nicholas J. White, F.R.S.
doi : 10.1056/NEJMe2110659
N Engl J Med 2021; 385:1231-1232
Third Time’s a Charm — Covid-19 Vaccine Hope for Solid-Organ Transplant Recipients
Winfred W. Williams, M.D., and Julie R. Ingelfinger, M.D.
doi : 10.1056/NEJMe2112866
N Engl J Med 2021; 385:1233-1234
Audio Interview: Vaccine Efficacy and Boosters in Covid-19
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2115556
N Engl J Med 2021; 385:e54
Controlled Human Infection Model — Fast Track to HCV Vaccine?
T. Jake Liang, M.D., Jordan J. Feld, M.D., Andrea L. Cox, M.D., Ph.D., and Charles M. Rice, Ph.D.
doi : 10.1056/NEJMsb2109093
N Engl J Med 2021; 385:1235-1240
Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance
Ron Bose, M.D., Ph.D., and Cynthia X. Ma, M.D., Ph.D.
doi : 10.1056/NEJMcibr2110552
N Engl J Med 2021; 385:1241-1243
Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients
doi : 10.1056/NEJMc2111462
N Engl J Med 2021; 385:1244-1246
MMR Vaccine–Associated Disseminated Measles in an Immunocompromised Adolescent
doi : 10.1056/NEJMc2103772
N Engl J Med 2021; 385:1246-1248
Therapy for Multisystem Inflammatory Syndrome in Children
doi : 10.1056/NEJMc2111096
N Engl J Med 2021; 385:e42
Health Care Worker Strikes and the Covid Pandemic
doi : 10.1056/NEJMc2111834
N Engl J Med 2021; 385:e43
Pathology of Racism — A Call to Desegregate Teaching Hospitals
Kavita Vinekar, M.D., M.P.H.
doi : 10.1056/NEJMpv2113508
N Engl J Med 2021; 385:e40
